Abbvie Inc. vs Royalty Pharma plc
ABBV vs RPRX — side-by-side comparison from reported financials. ABBV leads 5, RPRX leads 7 of 12 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Royalty Pharma plc
RPRX · Healthcare
$56.93+1.28%Solid
| Metric | ABBV | RPRX |
|---|---|---|
| Price | $276.43 | $56.93 |
| Market cap | $488B | $25.4B |
| Revenue (TTM) | $64.4B | $2.54B |
| Revenue growth | +1.8% | +2.1% |
| Net margin | 9.8% | 32.1% |
| Free cash flow | $18.2B | $2.98B |
| Net cash (debt) | ($56.2B) | ($7.93B) |
| 1-year price return | +19.8% | +57.5% |
| P/E | 77.4 | 40.2 |
| P/E vs own history (cheap-side %) | 23% | 53% |
| Dividend yield | 2.45% | 1.22% |
| Return on equity | 96% | 12% |
| Altman Z-score | 2.33 | 2.32 |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 57,000 | 100 |
Full résumé-style profiles: ABBV CV · RPRX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.